I forgot to include several other milestones/achievements in 2011 (i.e., the immuno-studies, director and adviser additions). Revising my scorecard for this year, we have:
- Liver: Orphan drug status (3 pts); enrollment (0.5), treatment (0.5) and study (1) completed;
- Psoriasis: Enrollment (0.5) and treatment (0.5) completed;
- Immunology: Study initiated (0.5) and completed (0.5); and,
- Corporate governance: Director (Smith) and adviser (Eagle) added (0.5).
We'll only appreciate the work carried out by management in 2011 as 2012 unfolds. Until then, we wait for the smoke from the fireworks to clear!